world-biomarkers-pharma-biotech-2017-posters

33 / 61

Notes:
Volume10, Issue 12 (Suppl) J Proteomics Bioinform, an open access journal
ISSN: 0974-276X
Page 89
conferenceseries.com
World Biomarkers & Pharma Biotech 2017
December 07-09, 2017
December 07-09, 2017 | Madrid, Spain
&
20th International Conference on
PHARMACEUTICAL BIOTECHNOLOGY
9th WORLD BIOMARKERS CONGRESS
JOINT EVENT ON
Measurement of serum EGF levels, a methodological approach: Learning what means low-/high
concentration of EGF in serum - Clinical implications
Idania González Pérez
Center of Molecular Immunology, Cuba
Background: Although the contribution of platelets to the measured serum epidermal growth factor (EGF) concentrations
([sEGF]) was reported since 1983, most of reports in healthy donors or patients do not control clotting times. This results in a
variation of the notified values, additionally to that caused by the functional polymorphism of the gene. Both issues platelets
and SNP make the conventional stratification by absolute sEGF levels not suitable. Within this study we evaluated the [sEGF]
in 105 healthy Cuban donors, balanced by gender and age (18-78 years). As a result, a new methodology of stratification of
individuals was proposed.
Methods: Sera were collected at two clotting times: 1h and 4h. Comparisons between groups by [sEGF] were carried out. The
estimations normalized through the calculation of its ratios r=[EGF]1h/[EGF]4h were used for the stratification.
Results: Differences were found by age ([EGF]4h, p=0.0083) and gender ([EGF]1h, p=0.0167), and between [EGF]1h and
[EGF]4h (p<0.0001).While 38 out of 105 individuals ranked different in 1h and 4h conventional stratifications, themethodology
using ratios yielded a unique score for each individual.
Conclusions: The proposed methodology of stratification by ratios, in contrast to the conventional approach, allows for a
proper comparison between EGF levels and individuals. Thus, it should have an impact on diseases for which the association
of EGF with the illness has been established, aiding to clarify the connection of the molecule with the disease. This work might
be of value to clinicians, scientists, and the healthcare community in general, conducting research regarding the role of EGF
as a biomarker.
Biography
Idania González Pérez has completed her BSc in Physics from the Faculty of Physics, Moscow State University, Russia (1985-1990) and Master of Science in
Physics and Mathematics from Faculty of Physics, Moscow State University, Russia. She is now involved in a PhD program at the University School of Medicine in
Havana. She is a Senior Researcher at the Center for Molecular Immunology in Havana, Systems Biology Department, Biomarkers Group. She has published more
than 15 papers in reputed journals and has been serving as a Reviewer in Medical Science Monitor, Journal of Hospital and Clinical Pharmacy and International
Blood Research & Reviews.
Idania González Pérez, J Proteomics Bioinform 2017, 10:12(Suppl)
DOI: 10.4172/0974-276X-C1-110